Breaking News

Financial Report: Hospira

May 1, 2013

Quality and product related charges contribute to losses

Hospira

1Q Revenues: $884.0 million (-9%)

1Q Loss: $76.6 million (earnings were $40.2 million 1Q12)

Comments: Specialty Injectable Pharmaceuticals sales were $651.5 million, up 11%. Medication Management revenues dropped 51% to $124.5 million. Other Pharma sales were $108.0 million, down 12%. Certain quality and product related charges primarily include third party oversight and consulting costs, extended production downtime related costs, failure to supply penalties, device product review and remediation costs to address identified issues, and costs for corrective actions including product recalls.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks